Archive \ Volume.14 2023 Issue 4

A Review Study on Chronic Inflammatory Demyelinating Polyneuropathy

, , , , ,
  1. Department of Therapy, Faculty of Pediatrics, Astrakhan State Medical University, Astrakhan, Russia
  2. Department of Therapy, Faculty of Medicine, Astrakhan State Medical University, Astrakhan, Russia


Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare immune-mediated disease in which an abnormal immune response causes demyelination and damage to the axons of peripheral nerves. This study is a systematic review of the literature. The screening of the abstracts was performed on the abstrackrBeta web-based software platform. The etiology, pathogenesis, modern methods of CIDP treatment, as well as the economic consequences of the spread of the disease, reflected in the scientific literature, are considered. Forty five 45 complete texts and nineteen conference procedures were found on the study of disease transmission n 9, humanistic burden n 7, current treatment n 40, and financial burden n 8 of CIDP. Epidemiological study have appeared the frequency and predominance of 0.2 1.6 and 0.8 8.9 per 100,000, depending on topography and symptomatic criteria. Six main types of therapy have been reported in publications on modern treatment methods: intravenous immunoglobulins, subcutaneous immunoglobulins, corticosteroids, plasmapheresis, immunosuppressants, and immunomodulators. According to the analyzed data, indications for the choice between these methods of treatment, as well as dosage regimens and frequency of use, have not been determined. Thus, CIDP is an autoimmune disease that requires constant monitoring and correction of therapy if necessary.

Downloads: 35
Views: 64

How to cite:
Baysurkaeva RA, Baykhanov GZ, Gelikhanov SO, Ostroushko VR, Kurbanova GF, Mamalieva EA. A Review Study on Chronic Inflammatory Demyelinating Polyneuropathy. Arch Pharm Pract. 2023;14(4):123-6.
Baysurkaeva, R. A., Baykhanov, G. Z., Gelikhanov, S. O., Ostroushko, V. R., Kurbanova, G. F., & Mamalieva, E. A. (2023). A Review Study on Chronic Inflammatory Demyelinating Polyneuropathy. Archives of Pharmacy Practice, 14(4), 123-126.

Download Citation
  1. Kuwabara S, Misawa S. Chronic Inflammatory Demyelinating Polyneuropathy. Adv Exp Med Biol. 2019;1190:333-43. doi:10.1007/978-981-32-9636-7_21
  2. Singh G, Goel N, Singh A, Gera R. Study of Factors Affecting the Time to Diagnosis and Treatment in Pediatric Acute Leukemia Patients- A study from India. Clin Cancer Investig J. 2022;11(3):35-40.
  3. Pradhan P, Senapati U, Sahoo SR, Parida S. Multifocal Giant Retroperitoneal Dedifferentiated Liposarcoma with dual heterologous dedifferentiation– a diagnostic and therapeutic challenge. Clin Cancer Investig J. 2022;11(3):21-4.
  4. Lehmann HC, Burke D, Kuwabara S. Chronic inflammatory demyelinating polyneuropathy: update on diagnosis, immunopathogenesis and treatment. J Neurol Neurosurg Psychiatry. 2019;90(9):981-7. doi:10.1136/jnnp-2019-320314
  5. Stino AM, Naddaf E, Dyck PJ, Dyck PJB. Chronic inflammatory demyelinating polyradiculoneuropathy-Diagnostic pitfalls and treatment approach. Muscle Nerve. 2021;63(2):157-69. doi:10.1002/mus.27046
  6. Querol L, Crabtree M, Herepath M, Priedane E, Viejo Viejo I, Agush S, et al. Systematic literature review of the burden of illness in chronic inflammatory demyelinating polyneuropathy (CIDP). J Neurol. 2021;268(10):3706-16. doi:10.1007/s00415-020-09998-8
  7. Rodríguez Y, Vatti N, Ramírez-Santana C, Chang C, Mancera-Páez O, Gershwin ME, et al. Chronic inflammatory demyelinating polyneuropathy as an autoimmune disease. J Autoimmun. 2019;102:8-37. doi:10.1016/j.jaut.2019.04.021
  8. Rajabally YA, Ghasemi M. Comparative value and determinants of the suitability of outcome measures in treated chronic inflammatory demyelinating polyneuropathy. Muscle Nerve. 2020;61(2):182-6. doi:10.1002/mus.26747
  9. Van den Bergh PYK, van Doorn PA, Hadden RDM, Avau B, Vankrunkelsven P, Allen JA, et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosing and treating chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force-Second revision. J Peripher Nerv Syst. 2021;26(3):242-68. doi:10.1111/jns.12455
  10. AlHussain BS, AlFantoukh MAM, Alasmari KMA, AlHrab FA, Alotaibi FA, Alaybani WH, et al. Clinical Knowledge of Orthodontics Complications and Emergencies Among Interns and Dentists in Riyadh City. Ann Dent Spec. 2022;10(2):45-51.
  11. Zahid TM, Khan NS. Myrrh and Chlorhexidine Mouthwashes Comparison for Plaque, Gingivitis and Inflammation Reduction: A 3-Arm Randomized Controlled Trial. Ann Dent Spec. 2022;10(1):39-46.
  12. Hassan HHF. A Training Program on Emotional Adjustment and its Social Communication Effect in Children with Behavioral Disorders. J Organ Behav Res. 2021;6(1):203-19.
  13. Rajabally YA, Attarian S, Delmont E. Evolving Immunologic Perspectives in Chronic Inflammatory Demyelinating Polyneuropathy. J Inflamm Res. 2020;13:543-9. doi:10.2147/JIR.S224781
  14. Gabriela AT, Lorena C, Vasile N, Olimpia PI, Claudia LC, Dan TR, et al. Risk factors of subclinical atherosclerosis in obesity and overweight. JPMA. 2020;70(5):840-4.
  15. Müller-Fabian A, Siserman C, Anițan ȘM, Delcea C. Juvenile delinquency in light of data recorded at the Institute of Forensic Medicine. Romanian J Legal Med. 2018;26(1):70-5.
  16. Broers MC, Bunschoten C, Nieboer D, Lingsma HF, Jacobs BC. Incidence and Prevalence of Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Systematic Review and Meta-Analysis. Neuroepidemiology. 2019;52(3-4):161-72. doi:10.1159/000494291
  17. Moss KR, Bopp TS, Johnson AE, Höke A. New evidence for secondary axonal degeneration in demyelinating neuropathies. Neurosci Lett. 2021;744:135595. doi:10.1016/j.neulet.2020.135595
  18. Koike H, Katsuno M. Pathophysiology of Chronic Inflammatory Demyelinating Polyneuropathy: Insights into Classification and Therapeutic Strategy. Neurol Ther. 2020;9(2):213-27. doi:10.1007/s40120-020-00190-8
  19. Blinov AV, Kachanov MD, Gvozdenko AA, Nagdalian AA, Blinova AA, Rekhman ZA, et al. Synthesis and Characterization of Zinc Oxide Nanoparticles Stabilized with Biopolymers for Application in Wound-Healing Mixed Gels. Gels. 2023;9(1):57. doi:10.3390/gels9010057
  20. Svačina MKR, Lehmann HC. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): Current Therapies and Future Approaches. Curr Pharm Des. 2022;28(11):854-62. doi:10.2174/1381612828666220325102840
  21. Svačina MKR, Mehndiratta MM, Vedeler CA, Sharma Y, Bobylev I, Sprenger A, et al. Clinical management of chronic inflammatory demyelinating polyneuropathy (CIDP) in Europe and India: An exploratory study. J Neurol Sci. 2021;427:117507. doi:10.1016/j.jns.2021.117507
  22. Bjelica B, Peric S, Bozovic I, Kacar A, Cobeljic M, Dejanovic I, et al. One-year follow-up study of neuropathic pain in chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst. 2019;24(2):180-6. doi:10.1111/jns.12318
  23. Allen JA, Gelinas DF, Freimer M, Runken MC, Wolfe GI. Immunoglobulin administration for the treatment of CIDP: IVIG or SCIG? J Neurol Sci. 2020;408:116497. doi:10.1016/j.jns.2019.116497
  24. Khandia R, Pandey MK, Zaki MEA, Al-Hussain SA, Baklanov I, Gurjar P. Application of codon usage and context analysis in genes up or down-regulated neurodegeneration and cancer to combat comorbidities. Front Mol Neurosci. 2023;16:1200523. doi:10.3389/fnmol.2023.1200523
  25. Kapugi M, Cunningham K. Corticosteroids. Orthop Nurs. 2019;38(5):336-9. doi:10.1097/NOR.0000000000000595
  26. Khandia R, Ali Khan A, Alexiou A, Povetkin SN, Verevkina MN. Codon Usage Analysis of Pro-Apoptotic Bim Gene Isoforms. J Alzheimers Dis. 2022;86(4):1711-25. doi:10.3233/JAD-215691
  27. Raevskaya AI, Belyalova AA, Shevchenko PP, Karpov SM, Mishvelov AE, Simonov AN, et al. Cognitive Impairments in a Range of Somatic Diseases. Diagnostics, Modern Approach to Therapy. Pharmacophore. 2020;11(1):136-41.




Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.